Dogwood Therapeutics Enters Material Definitive Agreement
Ticker: DWTX · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1818844
| Field | Detail |
|---|---|
| Company | Dogwood Therapeutics, INC. (DWTX) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
Dogwood Therapeutics just signed a big deal, filing an 8-K on 3/12/25.
AI Summary
On March 12, 2025, Dogwood Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Virios Therapeutics, Inc., is a pharmaceutical preparations company incorporated in Delaware.
Why It Matters
This filing indicates a significant new contract or partnership for Dogwood Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial filing.
Key Numbers
- 001-39811 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-4314201 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Dogwood Therapeutics, Inc. (company) — Registrant
- Virios Therapeutics, Inc. (company) — Former company name
- March 12, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
What is the nature of the material definitive agreement entered into by Dogwood Therapeutics, Inc. on March 12, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into on March 12, 2025.
When was Dogwood Therapeutics, Inc. formerly known as Virios Therapeutics, Inc.?
The company's name was changed from Virios Therapeutics, Inc. on December 17, 2020.
What is Dogwood Therapeutics, Inc.'s Standard Industrial Classification code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where is Dogwood Therapeutics, Inc. headquartered?
The company's principal executive offices are located at 44 Milton Avenue, Alpharetta, GA 30009.
What is the filing date for this 8-K report?
This 8-K report was filed as of March 14, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding Dogwood Therapeutics, Inc. (DWTX).